世界の甲状腺疾患：診断および治療市場

世界の甲状腺疾患の診断および治療の市場規模は、2024年の155億米ドル、2025年の163億米ドルから、2025年から2030年までの予測期間中はCAGR 5.2％で推移し、2030年には210億米ドルに達すると予測されています。

北米市場は、2024年の66億米ドル、2025年の69億米ドルから、2025年から2030年までの予測期間中はCAGR 5.5%で推移し、2030年には91億米ドルに達すると予測されています。アジア太平洋市場は、2024年の30億米ドル、2025年の32億米ドルから、CAGR 6.4%で推移し、2030年には44億米ドルに達すると予測されています。

当レポートでは、世界の甲状腺疾患の診断および治療の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場サマリー

第2章 市場概要

• 概要
• 従来の技術と新しい技術
• 甲状腺疾患の診断
• 甲状腺疾患の治療
• ポーターのファイブフォース分析
• マクロ経済要因
• 高齢化人口
• 規制環境
• がんの発生率増加
• 政府の政策と協力

第3章 市場力学

• 市場促進要因
• 甲状腺がんの罹患率増加
• 甲状腺疾患の有病率の増加
• 甲状腺疾患に対する意識の高まりと政策イニシアチブ
• 個別化医療による甲状腺疾患の管理
• 市場抑制要因
• 治療の副作用
• 低所得地域でのアクセスの制限
• 市場機会
• AIの導入
• アドバンストセラピューティクス
• 市場の課題
• ヘルスケア格差と資金調達の課題
• 生涯にわたる投薬の必要性

第4章 規制状況

• 承認プロセス：米国
• 承認プロセス：EU
• 承認プロセス：アジア太平洋
• 医薬品の承認と規制
• レボチロキシンベースの治療
• 抗甲状腺薬
• 生物学的製剤およびバイオシミラーの規制
• 医療機器および診断に関する規制
• ポイントオブケア検査と臨床検査
• ウェアラブルおよびデジタルヘルスソリューション
• 将来の動向と規制の変更

第5章 新興技術と開発

• 概要
• 甲状腺疾患診断における新技術
• ハイブリッド特徴選択とディープラーニングフレームワーク
• 甲状腺および副甲状腺手術のための自己蛍光技術
• 再生医療とバイオエンジニアリング
• バイオウェアラブル技術
• モバイルアプリ
• 医薬品および医療機器の最近の承認と発売
• 特許分析
• 調査結果

第6章 市場セグメンテーション分析

• セグメンテーションの内訳
• 重要ポイント
• 市場分析：疾病別
• 甲状腺機能低下症
• 甲状腺機能亢進症
• 甲状腺がん
• その他
• 市場分析：タイプ別
• サマリー
• 診断
• 治療
• 市場分析：エンドユーザー別
• サマリー
• 病院・専門クリニック
• 小売薬局・オンライン薬局
• 研究・学術機関
• 在宅ケア
• 地理的内訳
• 市場分析：地域別
• サマリー
• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第7章 競合情報

• サマリー
• 主要企業の市場シェア
• 開発・戦略
• 協定・協力・パートナーシップ
• 買収

第8章 甲状腺疾患の診断および治療の産業における持続可能性：ESGの観点

• ESG：イントロダクション
• 主要企業の取り組み
• ESGリスク評価
• BCCによる見解

第9章 付録

• 調査手法
• 出典
• 略語
• 企業プロファイル
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• FRESENIUS SE & CO. KGAA
• GSK PLC.
• LILLY
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• SIEMENS HEALTHINEERS AG
• TERUMO CORP.
• 新興スタートアップ企業/市場破壊者

List of Tables

• Summary Table : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, Through 2030
• Table 1 : Incidence of Thyroid Cancer in 2022
• Table 2 : Hypothyroidism Prevalence in the U.S. based on Optum Administrative Claims Database, 2012-2019
• Table 3 : Guidelines on Diagnosis and Management of Genetic Disorders of Thyroid Hormone, European Thyroid Association, 2024
• Table 4 : Comparative of HFSDLF Framework and Other Approaches, 2025
• Table 5 : Published Patents on Thyroid Gland Disorders: Diagnostics and Treatment, January 2024-January 2025
• Table 6 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 7 : Global Market for Diagnostics and Treatment of Hypothyroidism, by Region, Through 2030
• Table 8 : Global Market for Diagnostics and Treatment of Hyperthyroidism, by Region, Through 2030
• Table 9 : FDA-Approved Drugs in Advanced RR-DTC, 2025
• Table 10 : Tyrosine Kinase Inhibitors Tested in Thyroid Cancers, 2025
• Table 11 : Global Market for Diagnostics and Treatment of Thyroid Cancer, by Region, Through 2030
• Table 12 : Global Market for Diagnostics and Treatment of Other Thyroid Gland Disorders, by Region, Through 2030
• Table 13 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 14 : Global Market for Diagnostics of Thyroid Gland Disorders, by Region, Through 2030
• Table 15 : Global Market for Diagnostics of Thyroid Gland Disorders, by Type, Through 2030
• Table 16 : Global Market for Blood Test Diagnostics of Thyroid Gland Disorders, by Region, Through 2030
• Table 17 : Global Market for Imaging Diagnostic Tests of Thyroid Gland Disorders, by Region, Through 2030
• Table 18 : Global Market for Treatment of Thyroid Gland Disorders, by Region, Through 2030
• Table 19 : Global Market for Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 20 : Global Market for Medication Treatment of Thyroid Gland Disorders, by Region, Through 2030
• Table 21 : Global Market for Thyroid Surgery, by Region, Through 2030
• Table 22 : Biologics in the Pipeline for Potential Use in the Treatment of TED, 2025
• Table 23 : Global Market for the Treatment of TED, by Region, Through 2030
• Table 24 : Global Market for RAI Treatment of Thyroid Gland Disorders, by Region, Through 2030
• Table 25 : Global Market for Other Treatments of Thyroid Gland Disorders, by Region, Through 2030
• Table 26 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
• Table 27 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Hospitals and Specialty Clinics, by Region, Through 2030
• Table 28 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Retail and Online Pharmacies, by Region, Through 2030
• Table 29 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Research and Academic Institutes, by Region, Through 2030
• Table 30 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Home Care Settings, by Region, Through 2030
• Table 31 : Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, Through 2030
• Table 32 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 33 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 34 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
• Table 35 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
• Table 36 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
• Table 37 : North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
• Table 38 : U.S. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 39 : U.S. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 40 : Canadian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 41 : Canadian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 42 : Mexican Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 43 : Mexican Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 44 : Demographic Patterns in Thyroid Medication Use per 10,000 Population in European Countries, 2022
• Table 45 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 46 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 47 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
• Table 48 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
• Table 49 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
• Table 50 : European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
• Table 51 : U.K. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 52 : U.K. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 53 : French Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 54 : French Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 55 : Italian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 56 : Italian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 57 : German Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 58 : German Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 59 : Spanish Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 60 : Spanish Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 61 : Rest of European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 62 : Rest of European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 63 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorder, by Disease, Through 2030
• Table 64 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 65 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
• Table 66 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
• Table 67 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
• Table 68 : Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
• Table 69 : Chinese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease Type, Through 2030
• Table 70 : Chinese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 71 : Indian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 72 : Indian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 73 : Japanese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 74 : Japanese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 75 : Australian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 76 : Australian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 77 : South Korean Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 78 : South Korean Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 79 : Rest of Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 80 : Rest of Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 81 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 82 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 83 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
• Table 84 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
• Table 85 : South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
• Table 86 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
• Table 87 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
• Table 88 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
• Table 89 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
• Table 90 : MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
• Table 91 : Leading Companies in the Market, 2024
• Table 92 : Agreements, Collaborations and Partnerships in the Diagnostics and Treatment of Thyroid Gland Disorder Industry, 2021-2025
• Table 93 : Acquisitions in the Diagnostics and Treatment for Thyroid Gland Disorder Industry, 2023-2024
• Table 94 : ESG Highlights, by Leading Companies, 2023 and 2024
• Table 95 : ESG Risk Rankings, 2024
• Table 96 : Report Information Sources
• Table 97 : Abbreviations Used in this Report
• Table 98 : Abbott: Company Snapshot
• Table 99 : Abbott: Financial Performance, FY 2023 and 2024
• Table 100 : Abbott: Product Portfolio
• Table 101 : Abbott: News/Key Developments 2023-2025
• Table 102 : AbbVie Inc.: Company Snapshot
• Table 103 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 104 : AbbVie Inc.: Product Portfolio
• Table 105 : AbbVie Inc.: News/Key Developments, 2023 and 2024
• Table 106 : Amgen Inc.: Company Snapshot
• Table 107 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 108 : Amgen Inc.: Product Portfolio
• Table 109 : Amgen Inc.: News/Key Developments, 2021-2024
• Table 110 : AstraZeneca: Company Snapshot
• Table 111 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 112 : AstraZeneca: Product Portfolio
• Table 113 : AstraZeneca: News/Key Developments, 2021-2024
• Table 114 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 115 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 116 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 117 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
• Table 118 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 119 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 120 : F. Hoffmann-La Roche Ltd. : Product Portfolio
• Table 121 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
• Table 122 : Fresenius SE & Co. KGaA: Company Snapshot
• Table 123 : Fresenius SE & Co. KGaA: Financial Performance, FY 2023 and 2024
• Table 124 : Fresenius SE & Co. KGaA: Product Portfolio
• Table 125 : Fresenius SE & Co. KGaA: News/Key Developments, 2023 and 2024
• Table 126 : GSK plc.: Company Snapshot
• Table 127 : GSK plc.: Financial Performance, FY 2023 and 2024
• Table 128 : GSK plc.: Product Portfolio
• Table 129 : GSK plc.: News/Key Developments, 2021-2024
• Table 130 : Lilly: Company Snapshot
• Table 131 : Lilly: Financial Performance, FY 2023 and 2024
• Table 132 : Lilly: Product Portfolio
• Table 133 : Lilly: News/Key Developments, 2023 and 2024
• Table 134 : Merck KGaA.: Company Snapshot
• Table 135 : Merck KGaA.: Financial Performance, FY 2023 and 2024
• Table 136 : Merck KGaA: Product Portfolio
• Table 137 : Merck KGaA.: News/Key Developments, 2021-2023
• Table 138 : Novartis AG: Company Snapshot
• Table 139 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 140 : Novartis AG: Product Portfolio
• Table 141 : Novartis AG: News/Key Developments, 2022-2024
• Table 142 : Pfizer Inc.: Company Snapshot
• Table 143 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 144 : Pfizer Inc.: Product Portfolio
• Table 145 : Pfizer Inc.: News/Key Developments, 2022-2024
• Table 146 : Sanofi: Company Snapshot
• Table 147 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 148 : Sanofi: Product Portfolio
• Table 149 : Sanofi: News/Key Developments, 2022 and 2023
• Table 150 : Siemens Healthineers AG: Company Snapshot
• Table 151 : Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
• Table 152 : Siemens Healthineers AG: Product Portfolio
• Table 153 : Siemens Healthineers AG: News/Key Developments, 2024
• Table 154 : Terumo Corp.: Company Snapshot
• Table 155 : Terumo Corp.: Financial Performance, FY 2022 and 2023
• Table 156 : Terumo Corp.: Product Portfolio
• Table 157 : Terumo Corp.: News/Key Developments, 2023
• Table 158 : Emerging Startups

List of Figures

• Summary Figure : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, 2024
• Figure 1 : Existing and Emerging Technologies for the Treatment of Thyroid Disorders
• Figure 2 : Porter's Five Forces Market Analysis
• Figure 3 : Market Dynamics of Thyroid Gland Disorders
• Figure 4 : Shares of Global Thyroid Cancer Mortality in Males, by Region, 2022
• Figure 5 : Thyroid Health Awareness in the Saudi Population: A Community Study
• Figure 6 : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, 2024
• Figure 7 : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, 2024
• Figure 8 : Shares of Global Market for Diagnostics of Thyroid Gland Disorders, by Type, 2024
• Figure 9 : Shares of Global Market for Treatment of Thyroid Gland Disorders by Type, 2024
• Figure 10 : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, 2024
• Figure 11 : Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, 2024
• Figure 12 : North American Market Shares for Diagnostics and Treatment of Thyroid Gland Disorder, by Country, 2024
• Figure 13 : European Market Shares for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, 2024
• Figure 14 : Asia-Pacific Market Shares for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, 2024
• Figure 15 : Shares for Companies in the Market for Diagnostics and Treatment of Thyroid Gland Disorders, 2024
• Figure 16 : Abbott: Revenue Share, by Business Unit, FY 2024
• Figure 17 : Abbott: Revenue Share, by Country/Region, FY 2024
• Figure 18 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 19 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 20 : Amgen Inc.: Revenue Share, by Drug, FY 2024
• Figure 21 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 22 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
• Figure 23 : AstraZeneca: Revenue Share, by Region/Country, FY 2024
• Figure 24 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
• Figure 25 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
• Figure 26 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 28 : Fresenius SE & Co. KGaA: Revenue Share, by Business Unit, FY 2024
• Figure 29 : Fresenius SE & Co. KGaA: Revenue Share, by Country/Region, FY 2024
• Figure 30 : GSK plc.: Revenue Share, by Business Unit, FY 2024
• Figure 31 : GSK plc.: Revenue Share, by Country/Region, FY 2024
• Figure 32 : Lilly: Revenue Share, by Business Unit, FY 2024
• Figure 33 : Lilly: Revenue Share, by Country/Region, FY 2024
• Figure 34 : Merck KGaA: Revenue Share, by Business Unit, FY 2024
• Figure 35 : Merck KGaA.: Revenue Share, by Country/Region, FY 2024
• Figure 36 : Novartis AG: Revenue Share, by Business Unit, FY 2024
• Figure 37 : Novartis AG: Revenue Share, by Country/Region, FY 2024
• Figure 38 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 39 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 40 : Sanofi: Revenue Share, by Business Unit, FY 2024
• Figure 41 : Sanofi: Revenue Share, by Country/Region, FY 2024
• Figure 42 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024
• Figure 43 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024
• Figure 44 : Terumo Corp.: Revenue Share, by Business Unit, FY 2023
• Figure 45 : Terumo Corp.: Revenue Share, by Country/Region, FY 2023

The global market for diagnostics and treatment of thyroid gland disorders was valued at $15.5 billion in 2024 and is estimated to increase from $16.3 billion in 2025 to reach $21.0 billion by 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030.

The North American market for diagnostics and treatment of thyroid gland disorders was valued at $6.6 billion in 2024 and is estimated to increase from $6.9 billion in 2025 to reach $9.1 billion by 2030, at a CAGR of 5.5% from 2025 through 2030.

The Asia-Pacific market for diagnostics and treatment of thyroid gland disorders was valued at $3.0 billion in 2024 and is estimated to increase from $3.2 billion in 2025 to reach $4.4 billion by 2030, at a CAGR of 6.4% from 2025 through 2030.

Report Scope

The report analyzes trends in the global market for diagnostics and treatment of thyroid gland disorders. The report includes global revenue ($ million) for the base year 2024, estimated data for 2025, and for the forecast period of 2026 through 2030. The market is segmented by type of disease, product type, end user and region. The disease types are segmented into hypothyroidism, hyperthyroidism, thyroid cancer, and others. Product types are diagnostics and treatments. The diagnostics market is segmented into diagnostic, blood and imaging tests. The treatment market is segmented into medication, thyroid surgery, thyroid eye disease (TED) treatment and other end users are hospitals, specialty clinics, retail and online pharmacies, research and academic institutions, and patient and home care settings. The regions covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW. North American consists of the U.S., Canada, and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.

This report focuses on trends and challenges that affect the market, including emerging technologies. It includes an analysis of the competitive landscape, with the rankings and market shares of the leading companies in the global market. The report has a chapter on environmental, social, and corporate governance (ESG) developments and includes company profiles that covers key financials, product portfolios and recent news.

Report Includes

• 97 data tables and 62 additional tables
• An overview of the current and future global markets for thyroid gland disorder
• An analysis of the global market trends with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the size and revenue prospects of the global market, along with a market share analysis by type, disease type, end-user industry, and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
• Analysis of market opportunities from a Porter's Five Forces perspective, and a value chain analysis considering the prevailing micro- and macro environmental factors
• Coverage of advances in thyroid cancer diagnosis such as genomic tests and treatments, as well as the side effects of current treatments such as radioactive iodine
• Evaluation of ESG practices in the industry, consumer attitudes towards sustainability, risks and opportunity assessment, ratings and matrices
• A patent analysis with emphasis on emerging technologies and new developments in the market
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including Amgen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Bristol-Myers Squibb Co., and Pfizer Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Conventional and Novel Technologies
• Diagnostics in Thyroid Gland Disorders
• Treatment of Thyroid Gland Disorders
• Porter's Five Forces Analysis
• Potential for New Entrants (Moderate)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate to High)
• Threat of Substitutes (Low to Moderate)
• Industry Competitiveness (High)
• Macroeconomic Factors
• Aging Population
• Regulatory Environment
• Growing Incidence of Cancer
• Government Policy and Collaboration

Chapter 3 Market Dynamics

• Market Drivers
• Growing Prevalence of Thyroid Cancer
• Growing Prevalence of Thyroid Disorders
• Rising Awareness and Policy Initiatives for Thyroid Disorders
• Managing Thyroid Disorders through Personalized Medicine
• Market Restraints
• Side Effects of Treatment
• Limited Access in Low-Income Regions
• Market Opportunities
• Incorporation of AI
• Advanced Therapeutics
• Market Challenges
• Healthcare Disparities and Funding Challenges
• Requirement for Lifelong Medication

Chapter 4 Regulatory Landscape

• U.S. Approval Process
• EU Approval Process
• Asia-Pacific Approval Process
• Drug Approval and Regulations
• Levothyroxine-Based Treatments
• Anti-Thyroid Medications
• Biologic and Biosimilar Regulations
• Medical Devices and Diagnostics Regulations
• Point-of-Care and Laboratory Tests
• Wearable and Digital Health Solutions
• Future Trends and Regulatory Changes

Chapter 5 Emerging Technologies and Developments

• Overview
• Emerging Technologies in Thyroid Disorder Diagnostics
• Hybrid Feature Selection and Deep Learning Framework
• Autofluorescence Technology for Thyroid and Parathyroid Surgery
• Regenerative Medicine and Bioengineering
• Biowearable Technology
• Mobile Apps
• Recent Approvals and Launches of Drug and Device Products
• Patent Analysis
• Findings

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Key Takeaways
• Market Analysis by Disease Type
• Hypothyroidism
• Hyperthyroidism
• Thyroid Cancer
• Other Diseases
• Market Analysis by Type
• Takeaways
• Diagnostics
• Treatment
• Market Analysis by End User
• Takeaways
• Treatment in Hospitals and Specialty Clinics
• Retail and Online Pharmacies
• Research and Academic Institutes
• Home Care Settings
• Geographic Breakdown
• Market Analysis by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Takeaways
• Market Shares of Leading Companies
• Developments and Strategies
• Agreements, Collaborations and Partnerships
• Acquisitions

Chapter 8 Sustainability in the Diagnostics and Treatment of Thyroid Gland Disorders Industry: ESG Perspective

• Introduction to ESG
• Initiatives by Leading Companies
• ESG Risk Ratings
• BCC Research Viewpoint

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• FRESENIUS SE & CO. KGAA
• GSK PLC.
• LILLY
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• SANOFI
• SIEMENS HEALTHINEERS AG
• TERUMO CORP.
• Emerging Start-ups/ Market Disruptors